Firefly Perks on Hookup with Nvidia
Firefly Neuroscience, Inc. (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced its acceptance into the NVIDIA Connect program. Firefly expects to use the powerful new tools and resources provided through this prestigious program to help support a new strategic initiative to build a proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics (“BNA™”) technology platform, which harnesses Resting EEG and Cognitive EEG (ERP) data.NVIDIA Connect brings together NVIDIA’s (NASDAQ:NVDA) advanced software development resources, industry-leading frameworks and software development kits, and global ecosystem to help fuel the growth of member companies and expand the capabilities of their software development teams. Benefits include technical training and engineering guidance to support the development of products, and discounts on NVIDIA software and hardware to accelerate development and increase efficiency.“We are honored and excited to be among the select few medtech companies – big, medium or small – to be accepted into the prestigious NVIDIA Connect program,” said Greg Lipschitz, Executive Chairman of Firefly.Firefly is an Artificial Intelligence company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disordersAIFF shares hiked $1.33, or 42.9%, to $4.43, while those for NVDA gathered 38 cents to $133.95.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


